Related Experiment Videos
Prospective longitudinal analysis of quantitative Epstein-Barr virus polymerase chain reaction in pediatric liver
D L Kogan1, M Burroughs, S Emre
1Division of Pediatric Gastroenterology, Mount Sinai Medical Center, New York, New York 10029, USA.
Insights
Monitoring Epstein-Barr Virus (EBV) viremia in pediatric liver transplant patients using quantitative PCR can help detect viral load early. This early detection may prevent posttransplant lymphoproliferative disease (PTLD).
Area of Science:
- Pediatric Transplant Medicine
- Virology
- Immunology
Background:
- Posttransplant lymphoproliferative disease (PTLD) is a major cause of death in pediatric liver transplant recipients.
- Epstein-Barr Virus (EBV) mismatch increases PTLD risk, especially with newer transplant techniques.
- Early detection of EBV viremia is crucial for timely intervention.
Observation:
- Three pediatric liver transplant recipients were monitored monthly for EBV viral load.
- Quantitative competitive polymerase chain reactions (PCR) were used for EBV viral load measurement.
- EBV viremia onset was observed in one patient; established viremia in two others.
Findings:
- Quantitative PCR effectively tracked EBV viral load in pediatric liver transplant recipients.
- Early identification of EBV viremia was achieved through monthly monitoring.
- Two patients with established EBV viremia experienced chronic rejection and PTLD.
Implications:
- Quantitative PCR for EBV viral load shows promise in managing transplant recipients.
- Early EBV viremia detection may help prevent PTLD development.
- This monitoring strategy could improve outcomes for pediatric liver transplant patients.
Background:
Posttransplant lymphoproliferative disease (PTLD) remains a significant cause of morbidity and mortality in pediatric liver transplant recipients. Epstein-Barr Virus (EBV) mismatch associated with more prevalent use of split-liver, reduced size, and living-related transplants has increased the risk of primary EBV infection and subsequent PTLD. Early identification of EBV viremia may reduce the risk of PTLD, because it allows for early adjustment of immunosuppression and antiviral therapy.
Methods:
EBV viral load was measured monthly by quantitative competitive polymerase chain reactions in three pediatric liver transplant recipients.
Results:
Onset of EBV viremia was documented in one recipient. Established EBV viremia was followed in the other two recipients (one with chronic rejection and one with PTLD) who were initially tested once monitoring was initiated in our program.
Conclusions:
EBV quantitative competitive polymerase chain reactions may represent a promising way to follow EBV viral load and potentially prevent the development of PTLD.